Compound class:
Synthetic organic
Comment: KV-37 is as aldo-keto reductase 1C3 (AKR1C3) inhbitor [1]. Its androgen biosynthesis-inhibiting activity has shown encouraging synergistic therapeutic potential in combination with enzalutamide exposure in prostate cancer cells in vitro.
|
|
References |
1. Verma K, Gupta N, Zang T, Wangtrakluldee P, Srivastava SK, Penning TM, Trippier PC. (2018)
AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells. Mol Cancer Ther, 17 (9): 1833-1845. [PMID:29891491] |